1. lncRNA CYTOR promotes lung adenocarcinoma gemcitabine resistance and epithelial-mesenchymal transition by sponging miR-125a-5p and upregulating ANLN and RRM2
    Qijun Cao et al, 2024, Acta Biochimica et Biophysica Sinica CrossRef
  2. Long non-coding RNA LINC00152 in cancer: Roles, mechanisms, and chemotherapy and radiotherapy resistance
    Shuang Li et al, 2022, Frontiers in Oncology CrossRef
  3. The crosstalking of lactate‐Histone lactylation and tumor
    Yao Rong et al, 2023, PROTEOMICS – Clinical Applications CrossRef
  4. CYTOR-NFAT1 feedback loop regulates epithelial-mesenchymal transition of retinal pigment epithelial cells
    Rong Zhang et al, 2024, Human Cell CrossRef
  5. Identification of a Five-Autophagy-Related-lncRNA Signature as a Novel Prognostic Biomarker for Hepatocellular Carcinoma
    Xiaoyu Deng et al, 2021, Frontiers in Molecular Biosciences CrossRef
  6. The Role of Non-Coding RNAs in Breast Cancer Drug Resistance
    Jin-hai Tian et al, 2021, Frontiers in Oncology CrossRef
  7. Downregulation of the long noncoding RNA DSCR9 (Down syndrome critical region 9) delays breast cancer progression by modulating microRNA-504-5p-dependent G protein-coupled receptor 65
    Mingzhu Li et al, 2023, Human Cell CrossRef
  8. LINC00152: Potential driver oncogene in pan‐cancer
    Wei Xu et al, 2024, WIREs RNA CrossRef
  9. Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications
    Xuehao Zhou et al, 2022, Frontiers in Oncology CrossRef
  10. In vivo delivery of PBAE/ZIF-8 enhances the sensitivity of colorectal cancer to doxorubicin through sh-LncRNA ASB16-AS1
    Qing Yang et al, 2024, Journal of Biomaterials Science, Polymer Edition CrossRef
  11. miR-145-3p Hampers the Malignant Progression of Esophageal Carcinoma via CXCL5 Downregulation
    Gang Chen et al, 2022, Analytical Cellular Pathology CrossRef
  12. An angiogenesis-related lncRNA signature predicts the immune microenvironment and prognosis of breast cancer
    Ya-Wen Wang et al, 2023, Aging CrossRef
  13. DLGAP1-AS2 promotes estrogen receptor signalling and confers tamoxifen resistance in breast cancer
    Xiaoli Liang et al, 2022, Molecular Biology Reports CrossRef
  14. Advances in Understanding the LncRNA-Mediated Regulation of the Hippo Pathway in Cancer
    Mengwei Wang et al, 2021, OncoTargets and Therapy CrossRef
  15. Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer
    Jing Chen et al, 2021, Cancer Cell International CrossRef
  16. ELOVL2-AS1 suppresses tamoxifen resistance by sponging miR-1233-3p in breast cancer
    Hyeon Woo Kim et al, 2023, Epigenetics CrossRef
  17. Roles of zinc in cancers: From altered metabolism to therapeutic applications
    Mohamed Bendellaa et al, 2024, International Journal of Cancer CrossRef

  18. Long Non-Coding RNAs in Drug Resistance of Breast Cancer


    Tonghua Du et al, 2020, OncoTargets and Therapy CrossRef
  19. Dysregulation of Pseudogenes/lncRNA-Hsa-miR-1-3p-PAICS Pathway Promotes the Development of NSCLC
    Yichen Song et al, 2022, Journal of Oncology CrossRef
  20. Enterobacterial LPS-inducible LINC00152 is regulated by histone lactylation and promotes cancer cells invasion and migration
    Jianwei Wang et al, 2022, Frontiers in Cellular and Infection Microbiology CrossRef